HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Experts: E-cigarette regulations necessary to balance potential benefits, unknown harms
-
- The ‘puzzle’ of noncompliance: Skipped radiation and lives lost Joseph Ragaz, MD, FRCP
- Enzalutamide extends PFS in castration-resistant prostate cancer
- Small molecules, ‘big data’ and the EMR John Sweetenham, MD, FRCP, FACP
- FDA approves Jadenu for chronic iron overload
- FDA grants fast track status to anticoagulant reversal agent PER977
- FDA grants orphan drug designation to CRS-207 for mesothelioma
- FDA grants orphan drug designation to CUDC-907 for DLBCL
- FDA grants orphan drug designation to IMO-8400 for DLBCL
-
- FDA strengthens warning, changes prescribing instructions for Feraheme
- Adults with sickle cell disease display sleep disordered breathing
- Advanced breast cancer more likely in women with diabetes
- Advanced stage at diagnosis linked to worse lung adenocarcinoma OS
- Antivirals improve CMV pneumonia outcomes after HCT
- Benefits of tamoxifen for breast cancer prevention vary among at-risk women
- Boosted PIs lower Kaposi sarcoma incidence
- Changes in nevi were poor predictors of melanoma in children
-
- Combined-modality treatment effective for muscle-invasive bladder cancer
- Data support predictive significance of superficial vein thrombosis
- Encouraging male HPV vaccination may extend protection against HPV infection
- HSCT access limited by country, cost
- Metronomic temozolomide extends PFS, OS in EGFR-amplified glioblastoma
- Nomograms predict risk for tumor progression, death in imatinib-treated patients with GIST
- Older patients with HNSCC face higher toxicity risk from chemotherapy, radiation
- One-third of patients do not receive recommended post-mastectomy radiation
-
- Researchers identify age-associated risks for gastric, breast cancers with CDH1 mutations
- Women with IBD may face higher cervical cancer risk
- Adjuvant ipilimumab prolongs RFS in stage III melanoma
- Bevacizumab plus chemotherapy improves OS in recurrent ovarian cancer
- HD IL-2 extends OS in malignant melanoma
- Phase 3 trial to compare PV-10 with chemotherapy in stage III melanoma
- T-VEC extends OS in patients with unresected stage III/IV melanoma